{
    "clinical_study": {
        "@rank": "72076", 
        "acronym": "CLAU", 
        "arm_group": [
            {
                "arm_group_label": "Antiaggregants & Statins & Antihypertensives & Bosentan", 
                "arm_group_type": "Experimental", 
                "description": "Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy"
            }, 
            {
                "arm_group_label": "Antiaggregants & Statins & Antihypertensives", 
                "arm_group_type": "Active Comparator", 
                "description": "Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "A prospective study, proof-of concept, randomized, controlled, parallel groups, simple blind\n      was  performed in 30 male patients (50-60 years old) with Intermittent Claudication\n      (Rutherford category 1-2) recently diagnosed and clinical manifestations not exceeding 6\n      months with hypertension and/or dyslipidemia as unique co-morbility disorders. After a\n      period of stabilization of the claudication distance in the Stress test (12.5%, 3.2 km/h)\n      during 2 weeks, were randomized 1:1 to the experimental arm (Bosentan 62.5 mg twice\n      daily/four weeks and 125 mg twice daily/eight weeks) or control group."
        }, 
        "brief_title": "Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease", 
        "completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Intermittent Claudication", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Arterial hypertension and  hypercholesterolemia\n\n          -  ABI <0,9\n\n          -  Positive claudiometry with a claudication distance between 50 and 500\n\n        Exclusion Criteria:\n\n          -  surgical patient\n\n          -  Previous revascularization procedure in the Member studied\n\n          -  Smoker\n\n          -  Uncontrolled hypertension\n\n          -  Cardiac Stress Test unfinished\n\n          -  Prior DVT\n\n          -  Concomitant severe disease\n\n          -  Obesity"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738542", 
            "org_study_id": "NTC25102012", 
            "secondary_id": "E.C.13/2009.CEIC10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Antiaggregants & Statins & Antihypertensives & Bosentan", 
                "description": "Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)", 
                "intervention_name": "Bosentan", 
                "intervention_type": "Drug", 
                "other_name": "Tracleer"
            }, 
            {
                "arm_group_label": [
                    "Antiaggregants & Statins & Antihypertensives & Bosentan", 
                    "Antiaggregants & Statins & Antihypertensives"
                ], 
                "description": "AAS 100mg/d or Clopidogrel 75mg/d", 
                "intervention_name": "Antiaggregant therapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Antiaggregants & Statins & Antihypertensives & Bosentan", 
                    "Antiaggregants & Statins & Antihypertensives"
                ], 
                "intervention_name": "Statins", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Antiaggregants & Statins & Antihypertensives & Bosentan", 
                    "Antiaggregants & Statins & Antihypertensives"
                ], 
                "intervention_name": "Antihypertensive therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bosentan", 
                "Antihypertensive Agents", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bosentan", 
            "Peripheral Arterial Disease"
        ], 
        "lastchanged_date": "November 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Getafe", 
                    "country": "Spain", 
                    "state": "Madrid", 
                    "zip": "28901"
                }, 
                "name": "Hospital Universitario de Getafe"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease", 
        "other_outcome": [
            {
                "description": "To determine the efficacy of bosentan on the improvement in the endothelin function in patients with Intermittent Claudication due Peripheral Arterial Disease", 
                "measure": "Change in the serum levels of Endothelin (ET) respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "To determine the efficacy of bosentan on the improvement in inflammatory status in patients with Intermittent Claudication due Peripheral Arterial Disease.\nCRP for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months", 
                "measure": "Change in the serum levels of C-reactive protein (CRP) respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }
        ], 
        "overall_official": {
            "affiliation": "Hospital Universitario de Getafe", 
            "last_name": "De Haro Joaquin, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the efficacy of bosentan on the improvement in the absolute claudication distance in the exercise in patients with Intermittent Claudication due Peripheral Arterial Disease.\nACD and percentage of change, both for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months", 
                "measure": "Change in Absolute Claudication Distance (ACD) respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "To determine the efficacy of bosentan on the improvement in the overall endothelin function in patients with Intermittent Claudication due Peripheral Arterial Disease\nFMAD for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months", 
                "measure": "Change in flow-mediated arterial dilation (FMAD) respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738542"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario Getafe", 
            "investigator_full_name": "Joaquin de Haro, M.D.", 
            "investigator_title": "Randomized controlled clinical trial of Bosentan in Intermittent Claudication in Peripheral Arterial Disease", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety of Bosentan in patients with Intermittent Claudication due Peripheral Arterial Disease.\nAnalytical values : plasma electrolyte values, hepatic function, renal function, coagulation profiles, peripheral blood cell count", 
                "measure": "Changes in Analytical plasma values at each visit respect baseline values", 
                "safety_issue": "Yes", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "Efficacy of bosentan on the improvement in the hemodynamic states in patients with Intermittent Claudication due Peripheral Arterial Disease.\nABI for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months", 
                "measure": "Change in the ankle brachial index (ABI) respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "Efficacy of bosentan on the improvement of functional status (symptoms of claudication) in patients with Intermittent Claudication due Peripheral Arterial Disease\nSCD for the treatment group and control group, at each visit after baseline : 1 month, 3 months, 6 months and 12 months", 
                "measure": "Change in subjective claudication distance (SCD) reported by the patient, as is defined in the Walking Impairment Questionnaire (WIQ), respect baseline values", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "description": "Safety of Bosentan in patients with Intermittent Claudication due Peripheral Arterial Disease.", 
                "measure": "Occurrence of Adverse events during the study", 
                "safety_issue": "Yes", 
                "time_frame": "1 Year"
            }
        ], 
        "source": "Hospital Universitario Getafe", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario Getafe", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}